The global blood plasma market size is expected to reach USD 54,787.67 million by 2032, according to a new study by Polaris Market Research. The report “Blood Plasma Market Share, Size, Trends, Industry Analysis Report, By Type (Albumin, Factor VIII, Factor IX, Immunoglobulin, Hyperimmune Globulin, Others); By Application; By End-Use; By Region; Segment Forecast, 2023- 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.
The blood plasma market is experiencing substantial growth due to the increasing prevalence of severe blood disorders, notably Hemophilia and Thalassemia, impacting hundreds of newborns annually. Blood plasma, the fluid component of blood, plays a crucial role in transporting various blood constituents and is particularly in demand from individuals with blood type A.B. It is used in treating burn, shock, trauma, and clotting disorders, aiding in blood volume, shock prevention, and clotting support. Pharmaceutical companies utilize plasma for producing treatments for bleeding disorders and immune deficiencies.
The market's expansion is driven by government initiatives, growing public awareness, research and development efforts, healthcare sector expansion, an aging population, and increased adoption of plasma-derived products. Plasma-derived products like coagulation factor VIII and immunoglobulins are essential for managing blood-related disorders. Research and development in advanced plasma-derived products, strategic manufacturing, technological advancements, a substantial patient base, and increased healthcare expenditure all contribute to the market's positive trajectory during the 2022 to 2032 forecast period.
Do you have any questions? Would you like to request a sample or make an inquiry before purchasing this report? Simply click the link below: https://www.polarismarketresearch.com/industry-analysis/global-blood-plasma-market/request-for-sample
The blood plasma market faces disruption from recombinant alternatives that offer treatments for various medical conditions without relying on human plasma. Biologically engineered proteins and clotting factors can be produced through recombinant technologies, reducing dependence on plasma. This competition can impact pricing and market share, as recombinant alternatives are perceived as safer, eliminating the risk of pathogen transmission associated with plasma-derived products in specific diseases and medical conditions.
Blood Plasma Market Report Highlights
Polaris Market Research has segmented the Blood Plasma market report based on Type, Application, End-User, and region:
Blood Plasma, Type Outlook (Revenue - USD Million, 2019 - 2032)
Blood Plasma, Application Outlook (Revenue - USD Million, 2019 - 2032)
Blood Plasma, End-User Outlook (Revenue - USD Million, 2019 - 2032)
Blood Plasma, Regional Outlook (Revenue - USD Million, 2019 - 2032)
Report Attributes |
Details |
Market size value in 2023 |
USD 29,421.48 million |
Revenue forecast in 2032 |
USD 54,787.67 million |
CAGR |
7.2% from 2022 – 2030 |
Base year |
2022 |
Historical data |
2019 – 2021 |
Forecast period |
2023 – 2032 |
Quantitative units |
Revenue in USD million and CAGR from 2023 to 2032 |
Segments covered |
By Type, By Application, By End-Use, By Region |
Regional scope |
North America, Europe, Asia Pacific, Latin America; Middle East & Africa |
Customization |
Report customization as per your requirements with respect to countries, region and segmentation. |
For Specific Research Requirements |